Drugs From Europe Will Be Hit With a 15% Tariff, But Key Details Are Still Cloudy

If you want to search Cost Curve back issues or link to anything you read here, the web links and archive are online at costcurve.beehiiv.com. You can subscribe there, too.

  Inflection Point The thorniest problem in biopharmaceuticals is the growing conflict between cost-effectiveness and budget impact. In other words, we increasingly have weapons against disease that are, objectively and

It’s a big 340B day, starting with a decision by a federal appeals court to side with Arkansas in a dispute with PhRMA.  Arkansas has a law that says that